静脉氯胺酮输注治疗神经病理性疼痛:有前景但需优化
本文综述静脉氯胺酮输注治疗神经病理性疼痛的临床证据,指出文献中输注方案差异大、难以直接比较和优选。分析提示较高总剂量、较长输注时间及联用咪达唑仑或可乐定可能延长镇痛持续时间,但缺乏高质量对照研究指导方案优化。
要点
- 氯胺酮输注可治疗神经病理性疼痛,但方案差异大,缺乏优化证据。
- 较高总剂量和较长输注时间与镇痛持续时间延长相关。
- 联用咪达唑仑或可乐定可减轻精神症状副作用。
核心结论
- 静脉氯胺酮输注可用于治疗神经病理性疼痛,但现有文献缺乏高质量比较证据指导方案优化。
研究设计与样本
- topical review,分析相关临床证据并用牛津循证医学中心证据等级对输注变量进行推荐分级。
主要发现
- 神经病理性疼痛缓解持续时间延长与较高氯胺酮总输注剂量相关。
- 缓解持续时间延长与较长输注持续时间相关,而输注速率似乎不是影响因素。
- 联用咪达唑仑和/或可乐定可减轻部分不愉快的精神模拟副作用。
关键数值与推荐
- 采用牛津循证医学中心证据等级对每个输注变量的临床推荐进行分层。
临床怎么用
- 临床可考虑静脉氯胺酮输注治疗神经病理性疼痛,但需注意方案差异大且缺乏优化指南。
- 可考虑联用咪达唑仑或可乐定以减轻精神模拟副作用。
局限性
- 缺乏旨在优化氯胺酮输注方案的高质量对照研究。
- 文献中输注方案差异大,难以直接比较和确定最优方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravenous ketamine infusions have been used extensively to treat often-intractable neuropathic pain conditions. Because there are many widely divergent ketamine infusion protocols described in the literature, the variation in these protocols presents a challenge for direct comparison of one protocol with another and in discerning an optimal protocol. Careful examination of the published literature suggests that ketamine infusions can be useful to treat neuropathic pain and that certain characteristics of ketamine infusions may be associated with better clinical outcomes. Increased duration of relief from neuropathic pain is associated with (1) higher total infused doses of ketamine; (2) prolonged infusion durations, although the rate of infusion does not appear to be a factor; and (3) coadministration of adjunct medications such as midazolam and/or clonidine that mitigate some of the unpleasant psychomimetic side effects. However, there are few studies designed to optimize ketamine infusion protocols by defining what an effective infusion protocol entails with regard to a respective neuropathic pain condition. Therefore, despite common clinical practice, the current state of the literature leaves the use of ketamine infusions without meaningful guidance from high-quality comparative evidence. The objectives of this topical review are to (1) analyze the available clinical evidence related to ketamine infusion protocols and (2) call for clinical studies to identify optimal ketamine infusion protocols tailored for individual neuropathic pain conditions. The Oxford Center for Evidence-Based Medicine classification for levels of evidence was used to stratify the grades of clinical recommendation for each infusion variable studied.
引用
- Maher DP, Chen L, Mao J, et al. Intravenous Ketamine Infusions for Neuropathic Pain Management: A Promising Therapy in Need of Optimization. Anesth Analg. 2017. PMID: 28067704. doi:10.1213/ANE.0000000000001787
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。